Sol-Gel Technologies (SLGL) Competitors $0.58 -0.02 (-3.33%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$0.57 -0.01 (-0.86%) As of 02/21/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends SLGL vs. ME, HOWL, IPSC, AADI, STTK, CTMX, VHAQ, CNTX, QNCX, and KRONShould you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include 23andMe (ME), Werewolf Therapeutics (HOWL), Century Therapeutics (IPSC), Aadi Bioscience (AADI), Shattuck Labs (STTK), CytomX Therapeutics (CTMX), Viveon Health Acquisition (VHAQ), Context Therapeutics (CNTX), Quince Therapeutics (QNCX), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical products" industry. Sol-Gel Technologies vs. 23andMe Werewolf Therapeutics Century Therapeutics Aadi Bioscience Shattuck Labs CytomX Therapeutics Viveon Health Acquisition Context Therapeutics Quince Therapeutics Kronos Bio Sol-Gel Technologies (NASDAQ:SLGL) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends. Do analysts rate SLGL or ME? Sol-Gel Technologies currently has a consensus target price of $5.00, indicating a potential upside of 762.07%. 23andMe has a consensus target price of $9.40, indicating a potential upside of 288.43%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than 23andMe.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.0023andMe 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Is SLGL or ME more profitable? Sol-Gel Technologies has a net margin of -81.75% compared to 23andMe's net margin of -183.39%. Sol-Gel Technologies' return on equity of -27.17% beat 23andMe's return on equity.Company Net Margins Return on Equity Return on Assets Sol-Gel Technologies-81.75% -27.17% -22.49% 23andMe -183.39%-170.07%-62.13% Which has higher valuation & earnings, SLGL or ME? Sol-Gel Technologies has higher earnings, but lower revenue than 23andMe. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSol-Gel Technologies$1.55M10.43-$27.24M-$0.34-1.7123andMe$219.64M0.30-$666.70M-$15.45-0.16 Which has more volatility and risk, SLGL or ME? Sol-Gel Technologies has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Does the MarketBeat Community favor SLGL or ME? Sol-Gel Technologies received 137 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 63.40% of users gave Sol-Gel Technologies an outperform vote while only 50.00% of users gave 23andMe an outperform vote. CompanyUnderperformOutperformSol-Gel TechnologiesOutperform Votes14963.40% Underperform Votes8636.60% 23andMeOutperform Votes1250.00% Underperform Votes1250.00% Do institutionals and insiders believe in SLGL or ME? 26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 36.1% of 23andMe shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by insiders. Comparatively, 26.3% of 23andMe shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor SLGL or ME? In the previous week, 23andMe had 6 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 6 mentions for 23andMe and 0 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.00 beat 23andMe's score of -0.24 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Overall Sentiment Sol-Gel Technologies Neutral 23andMe Neutral SummarySol-Gel Technologies beats 23andMe on 14 of the 18 factors compared between the two stocks. Get Sol-Gel Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLGL vs. The Competition Export to ExcelMetricSol-Gel TechnologiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.72M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-1.715.8226.1519.13Price / Sales10.43268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book0.356.717.644.62Net Income-$27.24M$138.55M$3.19B$245.94M7 Day Performance-4.92%-2.63%-2.11%-2.62%1 Month Performance-35.48%-2.33%-0.49%-2.15%1 Year Performance-47.75%-5.33%16.44%12.95% Sol-Gel Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLGLSol-Gel Technologies2.6005 of 5 stars$0.58-3.3%$5.00+762.1%-47.7%$16.72M$1.55M-1.7150Gap DownME23andMe1.3628 of 5 stars$2.55+3.2%$9.40+268.6%-81.9%$66.60M$208.78M-0.17770Analyst ForecastNews CoverageHOWLWerewolf Therapeutics2.194 of 5 stars$1.49-1.3%$9.33+526.4%-79.2%$66.40M$3.39M-0.9740IPSCCentury Therapeutics2.387 of 5 stars$0.77+2.8%$10.00+1,191.2%-82.5%$65.86M$2.68M-0.42170Positive NewsAADIAadi Bioscience0.7808 of 5 stars$2.59-0.8%$1.67-35.6%+49.2%$63.97M$25.07M-1.1440STTKShattuck Labs3.5468 of 5 stars$1.33+6.4%$8.67+551.6%-84.4%$63.49M$1.66M-0.87100News CoverageCTMXCytomX Therapeutics4.3458 of 5 stars$0.80-3.6%$5.77+624.9%-46.2%$62.32M$101.21M4.68170Positive NewsVHAQViveon Health AcquisitionN/A$11.00flatN/A+1.8%$62.26MN/A0.002High Trading VolumeCNTXContext Therapeutics1.2694 of 5 stars$0.82+1.9%$6.33+670.9%-32.6%$61.62MN/A-0.907News CoverageGap UpQNCXQuince Therapeutics2.1279 of 5 stars$1.40-1.4%$9.50+578.6%+4.5%$61.60MN/A-1.1360KRONKronos Bio3.4373 of 5 stars$1.02flat$1.63+59.3%-5.0%$61.55M$6.29M-0.71100Positive News Related Companies and Tools Related Companies 23andMe Alternatives Werewolf Therapeutics Alternatives Century Therapeutics Alternatives Aadi Bioscience Alternatives Shattuck Labs Alternatives CytomX Therapeutics Alternatives Viveon Health Acquisition Alternatives Context Therapeutics Alternatives Quince Therapeutics Alternatives Kronos Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLGL) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sol-Gel Technologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sol-Gel Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLGL Stock Alerts